CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Assess whether a Total Market Fund Outperform SP 500 in Retirement by examining diversification, fees, and long-term performance to guide your strategy.
28,302 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Looking for growth you can ride for years? This guide breaks down three powerhouse names—NVIDIA, Microsoft, and Alpha...
On March 2, energy and defense names spearheaded gains as oil jumped, while travel and leisure stocks softened. This ...
Stocks wobbled as a memory-chip selloff led by South Korea dragged down Micron and peers. This article breaks down wh...
A major portfolio pivot is unfolding as 13F data reveals a famous hedge fund manager changing course. Learn why billi...
Bank of America highlights Intel's underownership in fund portfolios, suggesting intel’s stock could push higher as o...
A leading global shipping ETF is drawing attention for its current yield and rebound potential as sea lanes remain vo...
Gold has surged roughly 50% in the past year, but most portfolios remain lightly exposed. State Street’s 2026 outlook...
As the U.S. nears its 250th birthday, Wendy Schmidt unveils a major science funding program aimed at accelerating bre...
April Social Security payments arrive on a staggered schedule tied to birth dates. The 2.8% COLA is offset by Medicar...
A market thinker known as the prophet ‘wired belt’ warns that AI-driven shifts are hollowing out knowledge-economy jo...
Investing in Iron Mountain offers a blend of durable revenue and a meaningful dividend. This guide breaks down how th...